bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
Laboratories around the world have paused regular work to pursue treatment for COVID-19. While there are still no evidence-based treatments available, scientists are evaluating a variety of options beyond supportive care.
Each piece of data contributes to a larger epidemiological picture that will not only help us fight new coronaviruses that emerge in the future, but other infectious diseases as well.
Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.
With the COVID-19 pandemic having reached over 170 countries, and cases skyrocketing in the United States and other nations, scientists around the world are working as fast as they can to develop a vaccine for SARS-CoV-2, the virus that causes COVID-19.
At this year’s World Anti-Microbial Resistance Congress, Dr. Tristan Timbrook delivered a...
WASH, which stands for water, sanitation, and hygiene, are basic...